Innovative tuberculosis control programmes
in prisons have reduced the prevalence of TB, and successfully provided
isoniazid preventive therapy and treatment for both drug-sensitive and drug-resistant
TB, researchers reported at the 42nd Union World Conference on Lung Health held
in Lille last
month.
Many countries have reported very high TB prevalence
in prisoners, and prisoners have a very high risk of TB acquisition and development
of active TB whilst in jail.
According to the World Health Organisation
(WHO), the level of TB in prisons has been reported to be up to 100 times
higher than that of the civilian population and TB in prisons may account for up
to 25% of a country’s burden of TB.
Prisons act as a reservoir for TB, as the
disease spreads quickly through overcrowded and poorly ventilated prisons to
the prisoners, and to the broader population through staff, visitors and
inadequately treated former inmates. It is estimated globally that there are 8
to 10 million people living in prisons every day, however 4 to 6 times this
number pass through prisons each year, because of the high turnover of the
population.
For example, a TB screening programme of
prisoners in Azerbaijan has found that for every 8300 prisoners screened, 263
TB cases would be found (a case notification rate of 3168 per 100 000),
including 232 new cases of TB. TB suspects are also screened for drug-resistant
TB (DR TB). Of the first 150 prisoners diagnosed with DR TB, 108 (72 %) were
cured, 12 (8%) died, 15 (10%) defaulted and 12 (8%) were treatment failures.
This compared to the Ukonga prison in
Tanzania where the Three I’s (Intensified case finding, TB infection control
and Isoniazid preventative therapy) have been implemented, where 121 cases of
TB were identified in the prison population of 6200 (a case notification rate
of 1951 per 100,000 for all forms of TB). The national rate for all forms of TB
in Tanzania of TB is 146 per 100 000. The notification rate of new smear
or bacteriological-positive TB in Ukonga prison was 806 per 100 000. The
treatment success rate in Ukonga prison for all forms of TB is 80%.
Azerbaijan’s prison population of 15,000 is made up of 52 penitentiary
institutions. TB hospitals support the prison system by providing the necessary
healthcare supply and training prison personnel and following up TB patients
once they have been released from prison. The prison system of Azerbaijan, which
has been hailed as a success in terms of TB control, has a long history of
collaborating with TB institutions and funders such as the Global Fund for
AIDS, TB and Malaria (GFATM) who provided funding for a Gene Expert diagnostic
machine and for a second level laboratory which is currently in the design
phases. The Global Fund also provides funding for DR-TB treatment, infection
control activities and the reconstruction of the TB and HIV departments,
according to WHO guidelines for the prevention of TB in prisons.
Since 1995, 11,067 TB drug-sensitive have
been placed on treatment in Azerbaijan
prisons, and treatment for drug-resistant TB has been provided for 418 patients
since 2007. Each prisoner is given a clinical examination on entrance and
regular mass screenings for TB, by questionnaire, are conducted annually in all
the prisons with laboratory examination of all TB suspects’ sputum
samples.
Tanzania’s
prison average occupancy is 45,000 inmates, although there is only authorised
accommodation for 27 653 inmates. Tanzania
hosts one of the highest absolute numbers of prisoners in sub-Saharan Africa,
after Ethiopia and Kenya
respectively. There is a high proportion of smear-negative TB prevalence and higher
HIV prevalence in Tanzania,
and researchers believe that that many TB patients within Tanzanian prisons are
either diagnosed late or are missed.
Tanzania
ranks 14th out of the 22 TB high burden countries, with an estimated
50% of TB patients being HIV co-infected. The national adult HIV prevalence is
estimated to be 5.7%. The Ukonga prison implements the 3 I’s in line with the
existing TB screening algorithm of the national TB programme. A TB screening questionnaire is used for all
HIV-infected prisoners and all TB suspects are assessed using smear microscopy
and chest x-ray. “This package leads to judicious treatment and the
interruption of the TB transmission cycle”, said Jan van den Hombergh from Tanzania.
TB services and HIV counselling, testing,
care and treatment are offered through a one-stop service at Ukonga, with support
from PharmAccess International under a grant from USAID. 2010 prisoners had
been tested for HIV and received their result with 747 patients currently on
ARVs. 88 HIV-infected prisoners had started TB treatment and 94 people were
receiving IPT since July 2011.
The Tanzanian authorities aim to have
integrated TB and HIV screening, diagnosis and treatment services at least in
each regional main prisons and for all prison sites to be fully computerised
for recoding and monitoring and evaluation purposes. Following the success of
the Ukonga prison, the 3 I’s will be implemented in the three main prisons in Tanzania. A
longitudinal study of the impact of early and regular TB screening and the
implementation of the 3I’s strategy is being planned.